sorafenib has been researched along with Rodent Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T | 1 |
| Azadbakht, A; Gharibzadeh, S; Hajighasemlou, S; Mirmoghtadaei, M; Muhammadnejad, S; Nikbakht, M; Pakzad, S; Seyhoun, I; Verdi, J | 1 |
2 other study(ies) available for sorafenib and Rodent Diseases
| Article | Year |
|---|---|
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; Fibrosarcoma; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Rodent Diseases; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Disease Models, Animal; Heterografts; Humans; Interleukin-10; Liver Neoplasms; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Rodent Diseases; Sorafenib; Tumor Necrosis Factor-alpha | 2022 |